On February 24, 2015 FORMA Therapeutics reported that it has successfully met a second objective under its strategic collaboration agreement with Celgene, triggering an undisclosed payment from Celgene (Press release, Forma Therapeutics, FEB 24, 2015, View Source [SID:1234509332]). In April 2013, FORMA and Celgene entered into a collaboration to discover, develop and commercialize drug candidates to regulate protein homeostasis targets. This collaboration enables Celgene to evaluate selected targets and lead assets in protein homeostasis pathways during preclinical development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics, said, "We are pleased to have identified novel chemical matter and robust chemical tool compounds which supported interrogation of the potential clinical utility for this target. Celgene’s steadfast commitment to oncology and novel areas of biology is testament to Celgene’s mission of improving the lives of patients worldwide. FORMA’s alliance with Celgene provides a unique opportunity to discover, advance and accelerate a broad pipeline of novel therapies to impact human health."
About Protein Homeostasis
Protein homeostasis, which is important in oncology, neurodegenerative and other disorders, involves a tightly regulated network of pathways controlling the biogenesis, folding, transport and degradation of proteins. Exploring the maintenance and regulation of such competing, yet integrated, biological pathways using a chemical biology approach should directly contribute to the understanding of diseases associated with excessive protein misfolding, aggregation and degradation.